Table 1.
Baseline patient and treatment characteristics
| IMRT cohort N=51 |
Proton cohort N=25 |
P Value | |
|---|---|---|---|
| Age at Radiation (Mean) | 10.0 | 7.8 | 0.15 |
| Gender | |||
| Male | 19 (37) | 13 (52) | 0.22 |
| Female | 32 (63) | 12 (48) | |
| Race | |||
| White | 41 (80) | 20 (80) | 0.95 |
| Black | 6 (12) | 3 (12) | |
| Asian | 3 (6) | 1 (4) | |
| Other | 1 (2) | 1 (4) | |
| Histology | |||
| Embryonal | 36 (71) | 24 (96) | 0.01 |
| Alveolar | 15 (29) | 1 (4) | |
| Tumor location | |||
| Parameningeal | 42 (82) | 17 (68) | 0.16 |
| Orbital | 6 (12) | 3 (12) | |
| Other head and neck | 3 (6) | 5 (20) | |
| Tumor size | |||
| <5cm | 27 (53) | 14 (56) | 0.80 |
| ≥5cm | 24 (47) | 11 (44) | |
| Nodal status | |||
| N0 | 25 (49) | 18 (72) | 0.06 |
| N1 | 26 (51) | 7 (28) | |
| Stage | |||
| 1 | 9 (18) | 8 (32) | 0.48 |
| 2 | 9 (18) | 5 (20) | |
| 3 | 23 (45) | 9 (36) | |
| 4 | 10 (20) | 3 (12) | |
| Group | |||
| 2 | 3 (6) | 2 (8) | 0.61 |
| 3 | 38 (75) | 20 (80) | |
| 4 | 10 (20) | 3 (12) | |
| Cyclophosphamide dose per cycle | |||
| Reduced | 16 (32) | 21 (88) | <0.0001 |
| Standard | 34 (68) | 3 (12) | |
| Cumulative alkylating agent dose | |||
| ≤20g/m2 | 28 (57) | 16 (70) | 0.31 |
| >20g/m2 | 21 (43) | 7 (30) |
Abbreviations: IMRT = intensity-modulated radiation therapy